Reality Check

MMIT Reality Check on Multiple Sclerosis (Jan 2019)

January 11, 2019

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for multiple sclerosis treatments shows that more than half of the lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions.

Trends: Contracting is prevalent among interferons, where formulary preference drives choice. Via AIS Health.

MMIT Reality Check on Immune Globulin PID (Jan 2019)

January 4, 2019

According to our recent payer coverage analysis for immune globulins for primary immunodeficiency (PID), combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for immune globulins for primary immunodeficiency (PID), combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access breakdown reveals that more than 38% of the covered lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions

Trends: The FDA gave an additional approval to Hizentra (immune globulin subcutaneous [human]) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy to prevent relapse of neuromuscular disability and impairment

MMIT Reality Check on Epilepsy (Dec 2018)

December 28, 2018

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for epilepsy treatments shows that almost 29% of the covered lives under the pharmacy benefit in commercial formularies have utilization management restrictions on epilepsy medications.

Trends: Epidiolex, the first FDA-approved treatment that contains a purified drug substance derived from marijuana, is now available in the U.S. Via AIS Health.

MMIT Reality Check on Alpha-1 Antitrypsin Deficiency (Dec 2018)

December 21, 2018

According to our recent payer coverage analysis for alpha-1 antitrypsin deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for alpha-1 antitrypsin deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for alpha-1 antitrypsin deficiency treatments shows that among the four medications covered under the medical benefit, only 16% of the lives have utilization management restrictions under Medicare policies.

Trends: The FDA allowed marketing of 23and Me, Inc’s Personal Genome Service Genetic Health Risk tests in 2017. The tests look for generic variants in a person’s saliva whose presence or absence can indicate a heightened risk for 10 conditions, including alpha-1 antitrypsin deficiency.

MMIT Reality Check on Prostate Cancer (Dec 2018)

December 14, 2018

According to our recent payer coverage analysis for prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for prostate cancer treatments shows that more than 82% of the lives under the medical benefit are covered without utilization management restriction under Medicare policies.

Trends: A U.S. district court ruled that patent claims for Zytiga were invalid. Janssen said it will appeal the decision, but generic versions of the drug could launch at-risk. Via AIS Health.

MMIT Reality Check on Cystic Fibrosis (Dec 2018)

December 7, 2018

According to our recent payer coverage analysis for cystic fibrosis (CF) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for cystic fibrosis (CF) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CF treatments shows that more than half of the covered lives under the pharmacy benefit in health exchange programs and Medicare formularies have some type of utilization management restriction.

Trends: Even with a host of medications to treat the condition, challenges to managing CF exist, including the high cost of care, drug burden and having to get multiple medicines from more than one pharmacy. Via AIS Health.